Skip to main navigation

Skip to content

Side Menu

About Us
Our Platform
Our Products
Our Programs
Patients and Physicians
Inside Seres
Open Positions
Investors and News
Contact Us

Press Releases

Seres' news, events and other information can be found throughout the pages below.

Investor Relations

Stock Information
News and Events
- Press Releases
- Events & Presentations
Financial Information
- SEC Filings
- Annual Reports
Corporate Governance
Shareholder Services

Press Releases

Keyword Search

Year

Apr 26, 2023

Seres Therapeutics and Nestlé Health Science Announce FDA Approval of VOWST™ (fecal microbiota spores, live-brpk) for Prevention of Recurrence of C. difficile Infection in Adults Following Antibacterial Treatment for Recurrent CDI

Apr 07, 2023

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 09, 2023

Seres Therapeutics to Participate in Oppenheimer 33rd Annual Healthcare Conference

Mar 07, 2023

Seres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Mar 03, 2023

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 28, 2023

Seres Therapeutics to Host Fourth Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on March 7, 2023

Feb 27, 2023

Seres Therapeutics to Participate in Cowen 43rd Annual Health Care Conference

Feb 14, 2023

Seres Therapeutics’ Investigational SER-109 ECOSPOR IV Study Data Published in JAMA NETWORK OPEN

Feb 08, 2023

Seres Therapeutics Announces Initiation of Enrollment in SER-155 Phase 1b Study Cohort 2 in Individuals Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Feb 03, 2023

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pagination

First page
Previous page
Page 1
Page 2
Current page 3
Page 4
Next page
Last page

Shareholder Tools

RSS Feeds
E-mail Alerts
Print

© 2023 Seres Therapeutics.

Footer Left Menu

Privacy Policy
Terms of Use

Follow us on Linkedin
Follow us on Twitter
Follow us on Facebook